| pubmed-article:8245956 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8245956 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:8245956 | lifeskim:mentions | umls-concept:C0006104 | lld:lifeskim |
| pubmed-article:8245956 | lifeskim:mentions | umls-concept:C0205145 | lld:lifeskim |
| pubmed-article:8245956 | lifeskim:mentions | umls-concept:C0282151 | lld:lifeskim |
| pubmed-article:8245956 | lifeskim:mentions | umls-concept:C1167622 | lld:lifeskim |
| pubmed-article:8245956 | lifeskim:mentions | umls-concept:C0243144 | lld:lifeskim |
| pubmed-article:8245956 | lifeskim:mentions | umls-concept:C0140994 | lld:lifeskim |
| pubmed-article:8245956 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:8245956 | pubmed:dateCreated | 1993-12-23 | lld:pubmed |
| pubmed-article:8245956 | pubmed:abstractText | [125I]RTI-55 is a newly synthesized cocaine congener that may offer advantages over other ligands previously used to examine cocaine binding sites. However, the in vitro pharmacological and anatomical characterization of [125I]RTI-55 binding sites has not been previously performed in human brain. To determine the specificity, stability, and feasibility of [125I]RTI-55 for use in radioligand binding assays in postmortem human tissue, a series of experiments were performed characterizing [125I]RTI-55 binding sites in human brain using homogenized membrane preparations and quantitative autoradiography. Analysis of the association, dissociation, and saturation data favored two-phase processes. A curve-fitting analysis of the data derived in saturation experiments found a high-affinity site with KD = 66 +/- 35 pM and Bmax = 13.2 +/- 10.1 pmol/g of tissue and a low-affinity site with KD = 1.52 +/- 0.55 nM and Bmax of 47.5 +/- 11.2 pmol/g of tissue. Competition by ligands known to bind to the dopamine transporter showed a rank order of RTI-55 > GBR-12909 > maxindol > WIN 35428 > = methylphenidate > (-)-cocaine > buproprion > (+)-amphetamine. Binding to serotonergic sites was evaluated in the midbrain. Results of the saturation experiment performed autoradiographically in the midbrain showed a single site with KD = 370 +/- 84 pM. It appears that [125I]RTI-55 should be useful in further studies of the regulation of cocaine binding sites using postmortem human specimens. | lld:pubmed |
| pubmed-article:8245956 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8245956 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8245956 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8245956 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8245956 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8245956 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8245956 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8245956 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8245956 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8245956 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8245956 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8245956 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8245956 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8245956 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8245956 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8245956 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8245956 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:8245956 | pubmed:issn | 0022-3042 | lld:pubmed |
| pubmed-article:8245956 | pubmed:author | pubmed-author:BreeseG RGR | lld:pubmed |
| pubmed-article:8245956 | pubmed:author | pubmed-author:CarrollF IFI | lld:pubmed |
| pubmed-article:8245956 | pubmed:author | pubmed-author:DuncanG EGE | lld:pubmed |
| pubmed-article:8245956 | pubmed:author | pubmed-author:LittleK YKY | lld:pubmed |
| pubmed-article:8245956 | pubmed:author | pubmed-author:KirkmanJ AJA | lld:pubmed |
| pubmed-article:8245956 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8245956 | pubmed:volume | 61 | lld:pubmed |
| pubmed-article:8245956 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8245956 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8245956 | pubmed:pagination | 1996-2006 | lld:pubmed |
| pubmed-article:8245956 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:meshHeading | pubmed-meshheading:8245956-... | lld:pubmed |
| pubmed-article:8245956 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8245956 | pubmed:articleTitle | [125I]RTI-55 binding to cocaine-sensitive dopaminergic and serotonergic uptake sites in the human brain. | lld:pubmed |
| pubmed-article:8245956 | pubmed:affiliation | Department of Psychiatry, University of North Carolina at Chapel Hill. | lld:pubmed |
| pubmed-article:8245956 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8245956 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8245956 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8245956 | lld:pubmed |
